ArticleThe American journal of pathology2006
A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys.
Article in The American journal of pathology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 78 citations in OpenAlex.
- Emerging treatment for Sjögren's disease: a review of recent phase II and III trials.Expert opinion on emerging drugs · 2023Review
- Efficacy and Safety of Belimumab in Lupus Nephritis Patients: A Real-World Observational Study in China.Kidney diseases (Basel, Switzerland) · 2023Article
- Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization.Frontiers in immunology · 2021Review
- The activation of BAFF/APRIL system in spleen and lymph nodes of Plasmodium falciparum infected patients.Scientific reports · 2020Article
- Impact of BAFF Blockade on Inflammation, Germinal Center Reaction and Effector B-Cells During Acute SIV Infection.Frontiers in immunology · 2020Article
- Imaging Mass Cytometry and Single-Cell Genomics Reveal Differential Depletion and Repletion of B-Cell Populations Following Ofatumumab Treatment in Cynomolgus Monkeys.Frontiers in immunology · 2019Article
- Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies.Clinical reviews in allergy & immunology · 2018Review
- Current Insights in Microbiome Shifts in Sjogren's Syndrome and Possible Therapeutic Interventions.Frontiers in immunology · 2018Review
- Sjogren's syndrome: Review of the aetiology, Pathophysiology & Potential therapeutic interventions.Journal of clinical and experimental dentistry · 2017Review
- B-Cell-Activating Factor and the B-Cell Compartment in HIV/SIV Infection.Frontiers in immunology · 2017Review
- B-Cell Depletion Reduces the Maturation of Cerebral Cavernous Malformations in Murine Models.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2016Article
- B cells with regulatory properties in transplantation tolerance.World journal of transplantation · 2015Review
- Article
- New roles for the BLyS/BAFF family in antigen-experienced B cell niches.Cytokine & growth factor reviews · 2014Review
- Pharmacokinetics and pharmacodynamics of anti-BR3 monoclonal antibody in mice.Pharmaceutical research · 2012Article
- The discovery and development of belimumab: the anti-BLyS-lupus connection.Nature biotechnology · 2012Article
- Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE.Journal of biomedicine & biotechnology · 2012Review
- Tolerogenic therapies in transplantation.Frontiers in immunology · 2012Article
- B-cell-activating factor and autoimmune myasthenia gravis.Autoimmune diseases · 2011Article
- Innate pathways to B-cell activation and tolerance.Annals of the New York Academy of Sciences · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BAFF (also known as BLyS), a member of the tumor necrosis factor superfamily, plays a critical role in the maturation and development of B cells. BAFF has three receptors on B cells, the most crucial of which is BR3. In this study, we demonstrate the biological outcome of BAFF blockade in cynomolgus monkeys using a soluble fusion protein consisting of human BR3 and human IgG1 Fc. In vitro, BR3-Fc blocked BAFF-mediated survival and proliferation of cynomolgus monkey B cells. Weekly treatment of cynomolgus monkeys with BR3-Fc for 13 to 18 weeks resulted in significant B-cell reduction in the peripheral blood and in lymphoid organs. CD21(high) B cells in lymphoid tissues, a subset analogous to human marginal zone B cells, expressed nearly twofold higher BR3 levels than did CD21(med) B cells. Lymphoid tissue flow cytometric analysis showed that BR3-Fc reduced this CD21(high) B-cell subset to a greater extent than it reduced CD21(med) B cells. Dual-label immunohistochemistry and morphometric image analysis supported these results by demonstrating that BR3-Fc reduced a significant proportion of the B cells within the splenic inner and outer marginal zones. These findings should prove very useful in guiding the desired therapeutic use of BR3-Fc for autoimmune diseases in the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.